- Home
- CATX vs MCRB Comparison
CATX vs MCRB Comparison
Compare CATX & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- MCRB
- Stock Information
- Founded
- CATX 1983
- MCRB 2010
- Country
- CATX United States
- MCRB United States
- Employees
- CATX N/A
- MCRB N/A
- Industry
- CATX Medical/Dental Instruments
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- CATX Health Care
- MCRB Health Care
- Exchange
- CATX Nasdaq
- MCRB Nasdaq
- Market Cap
- CATX 133.3M
- MCRB 141.9M
- IPO Year
- CATX N/A
- MCRB 2015
- Fundamental
- Price
- CATX $1.94
- MCRB $0.37
- Analyst Decision
- CATX Strong Buy
- MCRB Hold
- Analyst Count
- CATX 10
- MCRB 5
- Target Price
- CATX $13.89
- MCRB $4.00
- AVG Volume (30 Days)
- CATX 950.5K
- MCRB 1.3M
- Earning Date
- CATX 05-12-2025
- MCRB 05-07-2025
- Dividend Yield
- CATX N/A
- MCRB N/A
- EPS Growth
- CATX N/A
- MCRB N/A
- EPS
- CATX N/A
- MCRB 0.00
- Revenue
- CATX $1,454,000.00
- MCRB N/A
- Revenue This Year
- CATX N/A
- MCRB N/A
- Revenue Next Year
- CATX $1.15
- MCRB N/A
- P/E Ratio
- CATX N/A
- MCRB $474.36
- Revenue Growth
- CATX 1.40
- MCRB N/A
- 52 Week Low
- CATX $1.60
- MCRB $0.46
- 52 Week High
- CATX $19.10
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- CATX 41.33
- MCRB 28.34
- Support Level
- CATX $1.60
- MCRB $0.36
- Resistance Level
- CATX $2.11
- MCRB $0.67
- Average True Range (ATR)
- CATX 0.21
- MCRB 0.07
- MACD
- CATX 0.03
- MCRB -0.02
- Stochastic Oscillator
- CATX 55.74
- MCRB 2.71
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.